Gencoglu, 2014 - Google Patents
Purification and effectiveness of vaccines and antiviral compoundsGencoglu, 2014
View PDF- Document ID
- 3540310637115015253
- Author
- Gencoglu M
- Publication year
External Links
Snippet
Viral infections account for over 13 millions deaths per year. Antiviral drugs and vaccines are the most effective method to treat viral diseases. Antiviral compounds have revolutionized the treatment of AIDS, and reduced the mortality rate. However, this disease still causes a …
- 229960005486 vaccines 0 title abstract description 161
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Anand et al. | Medicinal plants, phytochemicals, and herbs to combat viral pathogens including SARS-CoV-2 | |
| Besednova et al. | Antiviral effects of polyphenols from marine algae | |
| Tang et al. | Perilla (Perilla frutescens) leaf extract inhibits SARS-CoV-2 via direct virus inactivation | |
| Hebbani et al. | COVID-19: comprehensive review on mutations and current vaccines | |
| Periferakis et al. | Kaempferol: A review of current evidence of its antiviral potential | |
| Jannat et al. | Nanotechnology applications of flavonoids for viral diseases | |
| Mammari et al. | Plant-derived antimicrobial peptides as potential antiviral agents in systemic viral infections | |
| IL173071A0 (en) | Functional influenza virus-like particles (vlps) | |
| Sharma et al. | An insight into current treatment strategies, their limitations, and ongoing developments in vaccine technologies against herpes simplex infections | |
| AINANE | Moroccan traditional treatment for fever and influenza, similar to symptoms of coronavirus COVID-19 disease: Mini Review | |
| ES2426783T3 (en) | Aqueous Ribes extract for the treatment of viral infections | |
| Prabhu et al. | Cyanobacterial metabolites as novel drug candidates in corona viral therapies: A review | |
| Mahmoudi et al. | The novel drug discovery to combat COVID-19 by repressing important virus proteins involved in pathogenesis using medicinal herbal compounds | |
| Dash et al. | A scoping insight on potential prophylactics, vaccines and therapeutic weaponry for the ongoing novel coronavirus (COVID-19) pandemic-a comprehensive review | |
| Fernández Romero et al. | Algal and cyanobacterial lectins and their antimicrobial properties | |
| CN113194979B (en) | Antiviral compositions and methods | |
| JP7544801B2 (en) | Cyanobacterial extracts, methods for their preparation and use | |
| US20220395548A1 (en) | Hevamine-related plant compositions and methods | |
| CN102302484B (en) | Applications of isoflavone compound | |
| MX2008009117A (en) | Use of elderberry extract. | |
| Gencoglu | Purification and effectiveness of vaccines and antiviral compounds | |
| Iskarpatyoti et al. | Serotype-specific differences in inhibition of reovirus infectivity by human-milk glycans are determined by viral attachment protein σ1 | |
| Pu et al. | Antiviral activity of GuiQi polysaccharides against enterovirus 71 in vitro | |
| CN105943820A (en) | Traditional Chinese medicine compound for resisting swine influenza and porcine reproductive and respiratory syndrome and extraction method thereof | |
| Hasan et al. | Molecular docking of quassinoid compounds javanicolides AF and H with C3-like protease (or 3CLpro) of SARS and SARS-CoV-2 (COVID-19) and VP8* domain of the outer capsid protein VP4 of rotavirus A |